Affiliation: Cedars-Sinai Medical Center
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaSurasak Phuphanich
Neuro Oncology Program, Department of Neurosurgery and Neurology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Cancer Immunol Immunother 62:125-35. 2013....
- Phase 1 clinical trial of bortezomib in adults with recurrent malignant gliomaSurasak Phuphanich
The New Approaches to Brain Tumor Therapy Consortium, NABTT Central Office, 1550 Orleans Street, Suite 1M 16, Baltimore, MD 21231, USA
J Neurooncol 100:95-103. 2010..Some evidence of clinical activity was noted in this phase I study in patients with recurrent high grade gliomas...
- Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant gliomaSurasak Phuphanich
Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Neuro Oncol 10:617-23. 2008..Further study of atrasentan with radiation therapy and temozolomide in newly diagnosed GBM is warranted to evaluate the efficacy of this novel agent...
- Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomasStuart A Grossman
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
Neuro Oncol 10:608-16. 2008..The total body clearance of karenitecin is significantly enhanced by the concurrent administration of EIASDs. This schedule of karenitecin, a novel lipophilic camptothecin analogue, has little activity in recurrent MG...
- The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideStuart A Grossman
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
Clin Cancer Res 12:5174-81. 2006..This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD)...
- Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomasMichelle A Rudek
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
J Neurooncol 105:375-81. 2011..01). This study suggests that: (a) EIAD use does affect the pharmacokinetics of COL-3 at higher doses; and (b) there was not enough suggestion of single-agent activity to warrant further study in recurrent high-grade gliomas...
- Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor
Tracy T Batchelor, Rakesh K Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA Paul Mulholland, University College London, London Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium L Burt Nabors, University of Alabama at Birmingham, Birmingham, AL Mario Campone, Centre Rene Gauducheau, Saint Herblain, France Antje Wick, University of Heidelberg, Heidelberg, Germany Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada Tom Mikkelsen, Henry Ford Hospital, Detroit, MI Surasak Phuphanich, Cedars Sinai Medical Center, Los Angeles, CA Lynn S Ashby, Barrow Neurological Institute, Phoenix, AZ John DeGroot, MD Anderson Cancer Center, Houston, TX Lawrence Cher, Austin Health Cancer Services Mark Rosenthal, Royal Melbourne Hospital, Melbourne, 2-1 Hirosawa
J Clin Oncol 31:3212-8. 2013....
- A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingE Antonio Chiocca
The NABTT CNS Consortium, Baltimore, MD 21231, USA
Mol Ther 10:958-66. 2004..In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 10(10) pfu...
- Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrateMatthew J Baker
Neuro Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
J Neurooncol 59:239-42. 2002..Further studies should be considered to identify a subset of patients that have tumors sensitive to phenylbutyrate, either as a single agent or in combination with radiation therapy or other chemotherapeutic agents...
- Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeAlbert Lai
David Geffen School of Medicine at UCLA, Reed Neurological Research Center, Los Angeles, CA 90095, USA
J Clin Oncol 29:142-8. 2011..The objectives were to determine the efficacy of this treatment combination and the associated toxicity...
- Emerging molecular therapies for brain tumorsErwin G Van Meir
Department of Neurosurgery, Winship Cancer Institute Brain Tumor Program, Emory University, Atlanta, GA 30322, USA
Semin Oncol 31:38-46. 2004..These findings are now being translated into innovative clinical trials that provide new hope for patients with these devastating diseases...
- Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11Tracy T Batchelor
Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
Neuro Oncol 6:21-7. 2004..Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations...
- Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic studySurasak Phuphanich
The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Neuro Oncol 7:177-82. 2005..The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants...
- A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant gliomaMichael D Prados
Department of Neurological Surgery, University of California San Francisco, 94143, USA
Neuro Oncol 5:96-103. 2003..Recent preclinical pharmacokinetic modeling of RMP-7 suggests that higher doses of RMP-7 may be required to increase carboplatin delivery to tumor...
- Recurrent multicentric glioblastoma multiforme responds to thalidomide and chemotherapySurasak Phuphanich
Oncology (Williston Park) 16:276, 278. 2002
- Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastomaSteven Brem
Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33620, USA
Neuro Oncol 7:246-53. 2005..Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme...
- Treatment of neoplastic meningitis: what is the standard of care?Larry Recht
Stanford University Medical Center, 300 Pasteur Drive, Palo Alto, CA 94305, USA
Expert Rev Neurother 4:S11-7. 2004..will focus on defining the standard of care for neoplastic meningitis, including: What is the role of radiation therapy? What are first-line pharmacotherapeutic agents? Is combination therapy useful? What is the role of corticosteroids?..
- Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiationVictor A Levin
Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Neurooncol 78:295-302. 2006..Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas...
- Delivery systems and molecular targets of mechanism-based therapies for GBMSurasak Phuphanich
Department of Hematology Oncology, Winship Cancer Institute, Suite C 5002, 1365 C Clifton Road NE, Atlanta, GA 30322, USA
Expert Rev Neurother 4:649-63. 2004..Future goals are to tailor therapies to a tumor's molecular, proteomic or genomic status ,and manage glioblastoma multiformes as in chronic diseases in a multidisciplinary clinical setting...
- Treatment related myelitis in Hodgkin's lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literatureHeather Gatcombe
Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
J Neurooncol 79:293-8. 2006..We report here a case of a 25-year-old Middle Eastern man with progressive myelopathy 21 months following low dose irradiation of the cord in the context of high dose chemotherapy and stem cell rescue and a review of the literature...